Skye Bioscience

Q2 FY2026 EarningsQ2 FY26 results showed a narrower-than-expected operating loss of $11.06M compared to the $12.30M consensus, driven by the termination of the CBeyond trial and associated R&D cost-cutting. While revenue remained $0 as expected, GAAP EPS of -$0.27 missed the consensus mean of -$0.25 despite a beat on net income, likely due to share count assumptions. The period was defined by a major strategic pivot, including the announced acquisition of Redx Pharma and a $67.9M concurrent financing agreement to address a $0.57M working capital deficit.